Taysha Gene Therapies Share Holder Equity 2020-2024 | TSHA
Taysha Gene Therapies share holder equity from 2020 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
Taysha Gene Therapies Annual Share Holder Equity
(Millions of US $) |
| 2023 |
$75 |
| 2022 |
$1 |
| 2021 |
$95 |
| 2020 |
$251 |
| 2019 |
$-0 |
Taysha Gene Therapies Quarterly Share Holder Equity
(Millions of US $) |
| 2024-06-30 |
$109 |
| 2024-03-31 |
$54 |
| 2023-12-31 |
$75 |
| 2023-09-30 |
$-49 |
| 2023-06-30 |
$-37 |
| 2023-03-31 |
$-15 |
| 2022-12-31 |
$1 |
| 2022-09-30 |
$11 |
| 2022-06-30 |
$33 |
| 2022-03-31 |
$51 |
| 2021-12-31 |
$95 |
| 2021-09-30 |
$140 |
| 2021-06-30 |
$186 |
| 2021-03-31 |
$223 |
| 2020-12-31 |
$251 |
| 2020-09-30 |
$268 |
| 2020-06-30 |
$0 |
| 2020-03-31 |
$0 |
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.314B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
